利拉鲁肽治疗非酒精性脂肪性肝病的作用机制及研究进展  

Effect of liraglutide in treatment of non-alcoholic fatty liver disease： mechanism of action and research advances

作　　者：刘彦[1] 冯盼盼[2] 朱韦[2] 龚建平[2] 

机构地区：[1]成都市第五人民医院消化内科,611130 [2]重庆医科大学附属第二医院肝胆外科,400010

出　　处：《中华肝脏病杂志》2017年第6期473-476,共4页Chinese Journal of Hepatology

摘　　要：非酒精性脂肪性肝病是常见的慢性肝病，与肥胖、高脂血症、糖尿病等密切相关，可逐渐进展至肝硬化甚至肝细胞肝癌，然而目前尚无特效治疗药物。利拉鲁肽是人胰高血糖素样肽一1类似物，治疗2型糖尿病效果明确。目前很多研究结果显示利拉鲁肽在治疗2型糖尿病的同时对非酒精性脂肪性肝病有一定的治疗作用，但作用机制尚不明确。现就目前已经证实的利拉鲁肽对非酒精性脂肪性肝病的治疗作用机制进行综述。Non-alcoholic fatty liver disease is a common chronic liver disease closely associated with obesity, hyperlipidemia, and diabetes. It can gradually progress to liver cirrhosis or even hepatocellular carcinoma; however, there are still no specific therapeutic agents for this disease. Liraglutide is a human glucagon-like peptide- 1 analogue and has a marked effect in the treatment of type 2 diabetes. At present, many studies indicate that liraglutide also has a certain therapeutic effect on non-alcoholic fatty liver disease during the treatment of type 2 diabetes, but its mechanism of action remains unknown. This article reviews the known mechanisms of action of liraglutide in the treatment of non-alcoholic fatty liver disease.

关 键 词：脂肪肝 非酒精性 利拉鲁肽 胰岛素抵抗 

分 类 号：R575[医药卫生—消化系统]